Log on / register
Feedback | Support | My details
The Vpr protein from HIV-1: distinct roles along the viral life cycle.
Le Rouzic E, Benichou S
Retrovirology 2005, 2:11
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Induction of G2 arrest and binding to cyclophilin A are independent phenotypes of human immunodeficiency virus type 1 Vpr.
Ardon O, Zimmerman ES, Andersen JL, DeHart JL, Blackett J, Planelles V
J Virol 2006 Apr, 80:3694-700
 [PubMed Central] [PubMed] [Related articles]
2.
Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo.
Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, Mundt P, Williams SA, Warmerdam M, Kahn J, Hecht FM, Grant RM, de Noronha CM, Weyrich AS, Greene WC, Planelles V
J Virol 2006 Nov, 80:10407-18
 [PubMed Central] [PubMed] [Related articles]
3.
HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT.
Andersen JL, DeHart JL, Zimmerman ES, Ardon O, Kim B, Jacquot G, Benichou S, Planelles V
PLoS Pathog 2006 Dec, 2:e127
 [PubMed Central] [PubMed] [Related articles]
4.
*** Unable to retrieve article 17140287 ***

 [PubMed Central] [PubMed] [Related articles]
5.
Lentiviral Vpr usurps Cul4-DDB1[VprBP] E3 ubiquitin ligase to modulate cell cycle.
Hrecka K, Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, Florens L, Washburn MP, Skowronski J
Proc Natl Acad Sci U S A 2007 Jul 10, 104:11778-83
 [PubMed Central] [PubMed] [Related articles]
6.
HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase.
Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA
PLoS Pathog 2007 Jul, 3:e85
 [PubMed Central] [PubMed] [Related articles]
7.
*** Unable to retrieve article 17630831 ***

 [PubMed Central] [PubMed] [Related articles]
8.
DDB1 and Cul4A are required for human immunodeficiency virus type 1 Vpr-induced G2 arrest.
Tan L, Ehrlich E, Yu XF
J Virol 2007 Oct, 81:10822-30
 [PubMed Central] [PubMed] [Related articles]
9.
Human immunodeficiency virus type 1 Vpr links proteasomal degradation and checkpoint activation.
Dehart JL, Planelles V
J Virol 2008 Feb, 82:1066-72
 [PubMed Central] [PubMed] [Related articles]
10.
Lentiviral Vpx accessory factor targets VprBP/DCAF1 substrate adaptor for cullin 4 E3 ubiquitin ligase to enable macrophage infection.
Srivastava S, Swanson SK, Manel N, Florens L, Washburn MP, Skowronski J
PLoS Pathog 2008 May, 4:e1000059
 [PubMed Central] [PubMed] [Related articles]
11.
Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2.
Kamata M, Watanabe N, Nagaoka Y, Chen IS
J Virol 2008 Jun, 82:5672-82
 [PubMed Central] [PubMed] [Related articles]
12.
HIV VprR77Q mutation does not influence clinical response of individuals initiating highly active antiretroviral therapy.
Chui C, Cheung PK, Brumme CJ, Mo T, Brumme ZL, Montaner JS, Badley AD, Harrigan PR
AIDS Res Hum Retroviruses 2006 Jul, 22:615-8
 [PubMed Central] [PubMed] [Related articles]
13.
Characterization of the molecular determinants of primary HIV-1 Vpr proteins: impact of the Q65R and R77Q substitutions on Vpr functions.
Jacquot G, Le Rouzic E, Maidou-Peindara P, Maizy M, Lefrère JJ, Daneluzzi V, Monteiro-Filho CM, Hong D, Planelles V, Morand-Joubert L, Benichou S
PLoS One 2009, 4:e7514
 [PubMed Central] [PubMed] [Related articles]
14.
SIV Vpr evolution is inversely related to disease progression in a morphine-dependent rhesus macaque model of AIDS.
Noel RJ, Kumar A
Virology 2007 Mar 15, 359:397-404
 [PubMed Central] [PubMed] [Related articles]
15.
Uracil DNA Glycosylase 2 negatively regulates HIV-1 LTR transcription.
Fenard D, Houzet L, Bernard E, Tupin A, Brun S, Mougel M, Devaux C, Chazal N, Briant L
Nucleic Acids Res 2009 Oct, 37:6008-18
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 9 articles in BioMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.